ASH Clinical News ACN_4.1_FULL_ISSUE_DIGITAL | Page 64

On Location ASH Annual Meeting Salvage Regimen of Pomalidomide, Cyclophosphamide, and Dexamethasone Has High Response Rates in Lenalidomide-Refractory Myeloma Patients Eighty-five percent of patients with relapsed/refractory multiple myeloma (MM) achieved a partial remission (PR) or better (primary endpoint) when cyclophosphamide was a